Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Data In The Big Easy: Sapien Versus Surgery Results Get Top ACC Billing

This article was originally published in The Gray Sheet

Executive Summary

Transcatheter aortic heart valve data, and Edwards Lifesciences' Sapien valve in particular, are set to take the spotlight at yet another major cardiology conference this weekend.

You may also be interested in...

Abiomed: Cardiologists Will Respond To Positive Trends In Unfinished Impella Trial

Abiomed expects accelerated adoption of its Impella 2.5 circulatory support device based on partial data from a large study evaluating the system in high-risk, non-emergency angioplasty patients, despite having to stop the trial because it was deemed unlikely to meet its endpoint.

Edwards' Sapien Valve: Big Survival Boost In Those Too Sick For Surgery

Data from the first-ever randomized trial of a transcatheter aortic heart valve show a substantial one-year survival benefit for Edwards Lifesciences' Sapien versus standard medical therapy, giving the firm major momentum as it prepares to submit one of two upcoming PMAs for the device

Medtronic's Resolute Efficacy On Par With Abbott's Xience In One-Year Study

One-year efficacy results reported May 25 at the EuroPCR meeting in Paris could help Medtronic claim a bigger stake in the drug-eluting stent market, where Abbott and Boston Scientific have increasingly dominated

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts